BA
Biosergen AB Stock: price and insider trades · Sweden
Biosergen AB: what insiders have been doing
Biosergen AB has a thin disclosure history in our data (latest filing: 23 September 2022). New filings will appear here as soon as they are published. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
as of FY 2025FY ended December 2025 · cache
SEK 0.49
Analyst consensus
Income statement
EBITDA-SEK 38M
Net income-SEK 38M0.0% margin
Valuation
P/Book1.6x
Beta0.13
Balance sheet & cash
Market capSEK 40.7M
Free Cash Flow-SEK 36.8M
Profitability & ownership
ROE-194.2%
ROA-83.9%
% insiders1.6%
% institutions0.2%
Last declaration on 23 September 2022
Declarations1 total
- 901,334 shares0Teckningsrätt/UniträttISIN SE0018588238FI:csv-288739c0db0a401355e3
1 of 1 declaration
About Biosergen AB
Biosergen AB is a biopharmaceutical company focused on developing innovative treatments for fungal infections. It is listed on the Stockholm Stock Exchange.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations